---
title: "Peijia Medical Ltd. Announces Successful First Implantation in Clinical Trial of Sutra Hemi-valve Transcatheter Mitral Valve Repair System"
description: "Peijia Medical Ltd. has successfully completed the first implantation of its Sutra Hemi-valve Transcatheter Mitral Valve Repair System in a clinical trial at Waikato Hospital, New Zealand. The procedu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256913500.md"
published_at: "2025-09-11T11:35:14.000Z"
---

# Peijia Medical Ltd. Announces Successful First Implantation in Clinical Trial of Sutra Hemi-valve Transcatheter Mitral Valve Repair System

> Peijia Medical Ltd. has successfully completed the first implantation of its Sutra Hemi-valve Transcatheter Mitral Valve Repair System in a clinical trial at Waikato Hospital, New Zealand. The procedure was performed on an 83-year-old patient with severe functional mitral regurgitation. The patient recovered well and was discharged after three days. Peijia Medical, which has a strategic investment in Sutra Medical, Inc., notes that while this is a significant milestone, the successful development or marketing of the device is not guaranteed.

Peijia Medical Limited has announced the successful completion of the first implantation in the first-in-man clinical trial of its Sutra Hemi-valve Transcatheter Mitral Valve Repair System. The procedure was conducted at Waikato Hospital in New Zealand on an 83-year-old high-risk patient with severe functional mitral regurgitation, a condition for which conventional treatment options were unsuitable. The patient recovered well and was discharged from the hospital on the third day. The company, which holds a strategic investment in Sutra Medical, Inc., a U.S.-based medical device company, emphasizes that while this development marks significant progress, the successful development or marketing of the Sutra Hemi-valve cannot be guaranteed. Results of this clinical trial have been presented following the procedure. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peijia Medical Ltd. published the original content used to generate this news brief on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [09996.HK - PEIJIA-B](https://longbridge.com/en/quote/09996.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 沛嘉醫療為 GeminiOne TEER 系統提交歐盟 MDR CE 認證註冊 | 沛嘉醫療有限公司已提交其 GeminiOne 經導管邊緣對邊緣修復系統的歐盟醫療器械法規 CE 標誌申請，旨在治療二尖瓣關閉不全。此次提交是與歐洲合作伙伴 HighLife SAS 共同進行的。該產品也正在中國進行監管審查，並已獲得美國 F | [Link](https://longbridge.com/en/news/275242474.md) |
| 沛嘉醫療申請歐盟批准其心臟植入物 | 沛嘉醫療申請歐盟心臟植入物批准 | [Link](https://longbridge.com/en/news/275249808.md) |
| A 股上市公司紫光股份宣佈終止在港上市計劃 | 內地 A 股上市公司紫光股份宣佈終止在香港上市的計劃。該公司主要從事雲計算和 IT 基礎設施業務。去年 2 月，紫光股份曾選擇法巴、招銀國際及中信建投作為在港第二上市的安排，預計籌集約 10 億美元，但最終未能實現。 | [Link](https://longbridge.com/en/news/275716754.md) |
| 消息人士透露，Cfm 的股東 Safran 已將替代發動機設計命名為 “先進導管 - 大型” | Cfm 股東賽峯（Safran）已將替代發動機設計命名為 “先進導管大型”（advanced ducted-large），消息人士透露 | [Link](https://longbridge.com/en/news/275761600.md) |
| 哪些 AI 股票應該立即出售，以及應該購買哪些股票 | 湯姆·楊討論了人工智能股票，建議哪些應該出售，哪些應該購買。他用波士頓的一個傳統作為隱喻，強調保護有價值資產的重要性，將其比作在暴風雪後保存停車位。重點在於人工智能領域的戰略投資決策 | [Link](https://longbridge.com/en/news/275797000.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.